Antibody Construction Solution

'SBT Positively impacts commercial value of scFvs by Improving Product Success and Reducing Product Development Time'

Clinically Relevant Protein Reagents Made Better!

Platform production of clinically relevant reagents such as monoclonal antibodies (MAbs) and antibody-like proteins such as single chain antibody fragments (scFvs) can require years of dedicated laboratory work and millions of dollars!  StableBody Technologies, LLC (SBT) has developed a unique, state-of-the-art process for accelerating and achieving superior performance composition in antibody engineering.  When compared to MAbs use in clinical applications, SBT scFvs offer:


Improved Stability

Longer Shelf Life
Elevated Working Temperatures
Eliminate Cold Chain Storage and Distribution

Improved Affinity

Higher Sensitivity
Reduced Reagent Usage

Improved Efficiencies

Shorter production times

Reduced time to market
Reduced costs

Learn more >>>



The Future of scFvs

SBT has developed an elegantly simple, yet incredibly powerful method to design, engineer, and produce large numbers of structurally and functionally improved scFvs. This disruptive core technology can be directly applied to unmet protein engineering needs in many markets, including improved biothreat or environmental testing kits for defense applications, stabilized protein kits for clinical diagnostics which can be shipped/stored at ambient temperatures, and more potent therapeutic proteins to improve treatment efficacy and reduce reagent costs.   




StableBody Technologies, LLC

4675 Signature Drive

Middleton, WI  53562


H. Rossiter Horn, RPh

Chief Executive Officer